Introduction Noven Pharmaceuticals (Noven) is a specialty pharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription pharmaceutical products. The company markets a portfolio of hormone therapy products including Vivelle Dot, CombiPatch and Daytrana developed using its proprietary transdermal drug delivery technology, DOT Matrix. Scope - Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights Noven is focused on the development of transdermal drug delivery technology and prescription transdermal products. Vivelle Dot, CombiPatch and Daytrana are the company’s lead transdermal products. The company has a pipeline of drugs which it develops through its collaborators and licensees.The company’s total revenues increased at a CAGR of 2% during 2002-2006, from $55 million to $61 million mainly due to revenues recognized under product sales, contract fees, royalty and milestone payments from licensees including Novartis, Novogyne, Shire, and Aventis.Noven’s revenues are forecast to have an absolute growth of +$108 million with revenues of $61 million in 2006 increasing to $169 million in 2010 primarily due to product sales of Daytrana, Vivelle Dot, Pexeva and Stavzor and the license fees and other revenues earned in connection with the it’s collaborations with Novartis, Shire and Novogyne. Reasons to Purchase - Access all the important information and analysis on the company in a single report
- Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
TABLE OF CONTENTS Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 9
Company Financials 12
Stock Market Performance 12
P&L 14
Balance Sheet 18
Cash Flow 18
Geographic Segment Performance 19
Products & Services 20
Marketed Products 20
Pipeline products 22
AC Forecast Product Sales 25
Competitors and Strategic Business Relationships 27
Key Competitors 27
Key Suppliers 29
Key Clients 29
Shareholding Structure 30
Strategy 31
Company View 31
Corporate Strategy 39
SWOT Analysis 40
Overview 40
Strengths 41
Weaknesses 42
Opportunities 43
Threats 44
Value Chain Analysis 46
Overview 46
Discovery and Product Development 47
Manufacturing 47
Sales 47
Scorecard 48
Overview 48
Scorecard Analysis 49
Key Employees 50
List of Key Employees 50
Key Employee Biographies 51
Financial and Operational Overview 56
Financial and Operational Overview 56
APPENDIX 58
Ask the analyst 58
Datamonitor consulting 58
Disclaimer 58
TABLE OF FIGURES
Figure 1: Noven- Key Strategic Revenues, 2002-2006 ($ Mn) 14
Figure 2: Noven- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 15
Figure 3: Noven- Key Strategic Revenues, 2006-2010 ($ Mn) 25
TABLE OF TABLES
Table 1: Noven- Key Facts 6
Table 2: Noven- Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
Table 3: Noven- Key Events Impacting Share Price Performance 13
Table 4: Noven- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
Table 5: Noven- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 17
Table 6: Noven- Balance Sheet, 2002-2006 ($ Mn) 18
Table 7: Noven- Cash Flow, 2002-2006 ($ Mn) 18
Table 9: Noven- Marketed Products 20
Table 10: Noven- In-house Pipeline Products 22
Table 11: Noven- Collaboration Pipeline 24
Table 12: Noven- Key Strategic Revenues, 2006-2010 ($ Mn) 25
Table 13: Noven- Key Competitors 28
Table 14: Noven- Key Suppliers 29
Table 15: Noven- Key Clients 29
Table 16: Noven- Key Shareholders 30
Table 17: Noven- SWOT Analysis Summary 40
Table 18: Noven- Value Chain Analysis 46
Table 19: Noven- Scorecard 48
Table 20: Noven- Key Employees 50
Table 21: Noven- Financial and Operational Overview 56
Pages: 58
|
